Recent literature on the crystal-induced arthritides, gout and pseudogout, confirms initial speculation that Current Opinion in Rheumatology 2008, 20:66-75 Purpose of review The autoinflammatory diseases are a group of conditions that include the hereditary fever syndromes, and result from upregulated innate immune responses. The discovery of the genetic basis for these conditions led to the description of novel intracellular receptors for infectious and noninfectious danger signals. This article focuses on recent progress in our understanding of autoinflammatory syndromes, and how insights into these conditions have triggered the exploration of the role of innate immunity in common rheumatologic diseases.
Introduction
The concept of autoinflammatory diseases was introduced in the 1990s [1] . This concept encompasses a group of hereditary recurrent fever syndromes characterized by recurrent episodes of inflammation without evidence of the typical features of autoimmune diseases such as high titer autoantibodies or autoreactive T-cells [1] . In clinical practice, many patients who are eventually diagnosed with a hereditary recurrent fever syndrome are initially diagnosed as having 'fever of unknown origin', after an extensive workup excludes infections and malignancies. The initially described hereditary fever syndromes include familial Mediterranean fever (FMF) (Online Mendelian Inheritance in Man, OMIM 249100) (website: http:// www.ncbi.nlm.nih.gov), the cryopyrin-associated periodic syndromes (CAPS), namely, familial cold autoinflammatory syndrome (FCAS) (OMIM 120100), Muckle-Wells syndrome (MWS) (OMIM 191900) and neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurologic, cutaneous, articular (CINCA) syndrome (OMIM 607115), tumor necrosis factor (TNF) receptor associated periodic syndrome (TRAPS) (OMIM 191190) and hyperimmunoglobulinemia-D with periodic fever syndrome (HIDS) (OMIM 260920). Recently, the syndrome of pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) (OMIM 604416), Blau syndrome (OMIM 186580) and early-onset sarcoidosis (OMIM 609464) have been added as autoinflammatory syndromes all, however, present without recurrent fevers. We therefore use the more inclusive term 'monogenic autoinflammatory syndromes' to refer to all of these conditions. A list of the currently identified monogenic autoinflammatory syndromes and their clinical presentation and treatment has been given elsewhere [2] and they are listed in Table 1 .
Update on the genetics underlying monogenic autoinflammatory conditions
The appropriate evaluation of patients with suspected autoinflammatory syndromes can prove challenging. Two recent studies suggest that genetic testing should be reserved for patients with a clinical picture suggestive of a specific syndrome. In a European study involving specialist centers, a detailed clinical history suggesting one of the autoinflammatory syndromes, followed by targeted genetic testing, confirmed the diagnosis in 84 out of 87 patients in whom a clinical diagnosis had been made. In contrast, in 60 patients where the clinical history did not suggest a specific syndrome, screening for mutations in all the genes causing febrile autoinflammatory syndromes yielded just one possible diagnosis of FMF, and two cases with genetic variants, polymorphisms, rather than disease-causing mutations [4 ] . A French group [5] suggested that genetic screening for FMF should be considered only in patients of Mediterranean origin who meet the diagnosis of definite FMF based on the Israeli criteria [6] . Both of these studies reflect the extensive experience of clinicians in evaluating patients with potential autoinflammatory diseases. More significantly, they were conducted in countries with clearly defined ethnic groups, which may allow clinicians to identify specific autoinflammatory conditions with greater confidence based on clinical features alone. Indeed, it could be argued that in countries or ethnic groups with a high prevalence of a specific condition, such as FMF, patients with typical symptoms and signs do not require confirmatory genetic testing. Applying these study findings to clinical practice in countries with mixed populations is more problematic, however. The expansion of the clinical phenotypes of each of the autoinflammatory conditions and the recognition of these syndromes in patients with nonclassic ethnic backgrounds suggest that, in some circumstances, more liberal genetic testing is useful in deriving a diagnosis. The search for genetic causes of disease is a rapidly evolving field of research, with new mutations and functional polymorphisms being identified in both classical monogenic autoinflammatory syndromes and nonclassical syndromes. No generally accepted guidelines for genetic testing currently exist, and clinicians should bear in mind that the indications for genetic testing will change according to our evolving knowledge of these conditions. [7] . The authors suggest that this variant is not implicated in FMF, and that its identification should not lead to a false-positive diagnosis of FMF. Further research will be required to determine if this variant represents a functional polymorphism.
Cryopyrin-associated periodic syndrome NOMID, MWS and FCAS were traditionally considered distinct syndromes; however, their common genetic mutations in CIAS1, also called NLRP3/NALP3 and PYPAF1, and their overlapping clinical features such as urticaria-like skin rash, and varying degrees of systemic inflammation, indicate that these conditions lie along a clinical continuum [8 ] . NOMID has the most severe clinical phenotype and worst prognosis; FCAS is relatively mild with a good prognosis, and MWS lies in between. Only half of all patients with clinical NOMID have a demonstrable mutation in CIAS, which led to the exploration of the role of somatic mosaicism in causing NOMID [9] . In one NOMID patient with CNS disease, a somatic mutation resulted in the presence of Y570C change in only 16.7% of cells in whole blood. This mutation was previously described as a germline mutation in patients with NOMID [10] . In patients who are negative for mutations in CIAS1, screening for other candidate genes, including ASC, has proven negative to date [8 ,11 ] .
Tumor necrosis factor receptor-associated periodic syndrome
In patients with TRAPS, the interpretation of substitutions in TNFRSF1A can prove challenging. For example, the P46L substitution occurs in up to 20% of clinically asymptomatic individuals in a West African population, which suggests that in this population, it represents a polymorphism rather than a disease-causing mutation.
As in-vitro studies suggest a pro-inflammatory role, this polymorphism may confer a biologic advantage; however, its impact may differ according to varying genetic backgrounds. The clinical significance of another TNFRSF1A substitution, R92Q, was determined in family studies of patients with recurrent fevers. The R92Q genotype did not correlate with the TRAPS phenotype although it was associated with heterogeneous clinical symptoms. The authors therefore suggest that R92Q is a reduced penetrance variant, and that it may play a role in a wider spectrum of inflammatory disorders [12] .
Hyperimmunoglobulinemia-D with periodic fever syndrome HIDS was initially identified in the Netherlands, and is most prevalent in patients of Northwest European origin albeit with isolated cases in more diverse ethnic groups, with a recent report describing HIDS in two siblings from India [13] .
Advances in our understanding of the pathophysiology of monogenic autoinflammatory diseases
Several in-vitro models have been developed to better characterize the pathophysiologic pathways in these conditions.
Familial Mediterranean fever
The FMF-associated gene, MEFV, encodes the protein pyrin. The role of pyrin in the regulation of inflammation in healthy individuals and in the diseased state remains unclear but recent studies have provided insights into pyrin's complex interactions with numerous regulatory proteins. Pyrin is composed of four domains, which include the pyrin domain (PYD), B-box, coiled-coil, and B30.2 (also called SPRY) domains ( Fig. 1 ). Although mutations are found throughout MEFV, the most severe 68 Systemic disorders with rheumatic manifestations as monocytes differentiate into macrophages, pyrin protein expression diminishes with a parallel reduction in levels of IL-1b. All the above studies have been generated using in-vitro or murine models of disease, and the results may be explained by the changing role of pyrin depending on its cellular context. The relevance of these findings to human disease remains to be determined, however.
Cryopyrin-associated periodic syndrome
The disease manifestations of CAPS have been more clearly linked to the overexpression of the pro-inflammatory cytokine IL-1b. Although cryopyrin has not yet been crystallized, computer modeling of the structure suggests that wildtype cryopyrin forms an inactive closed-ring structure. This model predicts that the rings open following stimulation and autoaggregate to form a multiprotein complex called the inflammasome. Inflammasome formation results in the release of active IL-1b. In the disease state, mutant cryopyrin spontaneously adopts the open form, which results in inflammasome assembly with subsequent activation of caspase-1 and its enzymatic activation of IL-1b [8 ] .
The cold-induced inflammation seen in patients with FCAS was simulated ex vivo. Patient cells spontaneously released IL-1b in response to incubation at 328C, a result that was blocked by anakinra, and that confirmed that modest cold exposure can trigger IL-1b release in these patients [21] . The role of mutant CIAS1-induced necrosis described in an in-vitro model needs further evaluation [22] .
Tumor necrosis factor receptor-associated periodic syndrome 'Defective shedding' of the mutant TNF receptors (TNFR1) from the cell surface was found in a subset of patients with TRAPS. The decrease in receptor cleavage from the cell surface was thought to cause persistent pro-inflammatory cellular signaling and a relative lack of the anti-inflammatory soluble TNF receptor in serum [1] . Additional data suggest that mutant TNFR1 becomes misfolded and fails to travel to the cell surface but remains in the endoplasmic reticulum. This intracellular aggregation of mutant TNFR1 may lead to ligand-independent activation through the 'endoplasmic reticulum stress' response; alternatively, intracellular signaling complexes may form [23 ] . Neutrophils from patients with TRAPS fail to apoptose appropriately, thereby suggesting another mechanism by which the inflammatory response may be perpetuated [24 ] . 
Clinical aspects and treatment of the autoinflammatory diseases
Amyloidosis is an insidious complication of many autoinflammatory syndromes.
AA amyloidosis in autoinflammatory syndromes
The natural history of amyloidosis was recently summarized in a retrospective analysis of a national center's cohort of 374 patients of whom 32 (9%) had an autoinflammatory syndrome [28 ] . Other diagnoses included inflammatory arthritis, chronic infection, Crohn's disease and miscellaneous causes. Lower median serum amyloid A (SAA) levels and the regression in amyloid burden significantly correlated with decreased mortality and improved renal prognosis. Median SAA levels below 10 mg/l were associated with a decrease in amyloid deposits and superior survival, and a median SAA level of less than 4 mg/l had the lowest relative risk of death. These data suggest the value of serial SAA measurements in monitoring and guiding clinical care. SAA assays will require further certification to facilitate their use in the US.
In FMF, the MEFV genotype M694V has been most strongly associated with amyloidosis; an additional risk factor is the serum amyloid A 1a/a genotype. A physician survey in 14 countries collected data on 2482 genetically confirmed cases of FMF, which is estimated to represent over 50% of all genetically confirmed cases worldwide. The prevalence of renal amyloidosis was 11.4% [29 ] . In a multivariate analysis, the country of recruitment was the strongest predictor for amyloidosis, with a three-fold increased risk of amyloidosis for patients in Arabian countries, Turkey and Armenia compared with the US and West European countries. The association of amyloidosis and infant mortality rates by country suggests that a common environmental factor may underlie this phenomenon. Therefore the country should be considered for prophylactic colchicine therapy. Interestingly, one patient with the T50M mutation in TNFRSF1A who denied ever having had symptoms suggestive of TRAPS, including fever, developed AA amyloidosis [30].
The first three reports of amyloidosis in HIDS occurred almost simultaneously. One patient with HIDS and the SAA 1 a/a genotype developed a rapidly progressive pauci-immune glomerulonephritis and end-stage renal disease (ESRD). Although the renal biopsy was without evidence of amyloidosis, biopsies of the gastrointestinal and respiratory tracts confirmed AA amyloid deposits [31] . Two more patients with HIDS who developed AA amyloidosis resulting in ESRD were described [32] .
Current therapy in patients with amyloidosis focuses on controlling the underlying inflammation but the continued renal deterioration and death in a significant number of patients illustrate the unmet needs of this devastating condition. A new compound, eprodisate, which inhibits the formation and deposition of amyloid fibrils in tissue was evaluated in a 24-month-long, randomized, controlled trial involving 183 patients (20% with autoinflammatory syndromes). Those patients who received eprodisate had a slower decline in renal function. Eprodisate had no impact on the development of end-stage renal disease or death, the primary end-points for the trial [33 ] . The ability to slow the decline in renal function constitutes an advance. The lack of control for underlying anti-inflammatory treatment, however, an unequal distribution of patients with chronic infections and lower baseline serum C-reactive protein in the eprodisate group all suggest that further evaluation of this drug is required.
Cryopyrin-associated periodic syndrome and therapy
Evidence that overproduction of active IL-1b is the pivotal disease-causing mechanism in patients with CAPS comes from a number of recent publications. A prospective study [34 ] reported a dramatic response to the inhibition of IL-1 with anakinra in 18 patients with CIAS1 mutation-positive and negative NOMID. Not only did rash and acute-phase reactants improve, but the treatment also improved the neurologic disease manifestations, including headaches. Intracranial pressure, white-cell counts and protein levels decreased significantly in the patients in whom cerebrospinal fluid (CSF) was obtained, and hearing improved or remained stable in all evaluable patients. Withdrawal of therapy resulted in a rapid relapse of symptoms, suggesting that continuous inhibition of IL-1b is required. MRI sequences visualized leptomeningeal and cochlear inflammation and may assist in diagnosis and guide therapy. Data from an Italian registry [11 ] describe the clinical features and encouraging response to anakinra therapy in patients with NOMID. Seven of the 12 patients had significant perinatal events that contributed to the development of mental retardation. In common with other reports [8 ,35,36] , poor correlation in genotypephenotype between mutations and disease severity in patients with CAPS was found. The use of anakinra in other forms of CAPS is increasing, including its use in children with FCAS [37] . IL-6, a mediator of inflammation downstream of IL-1b in patients with NOMID, is elevated in the serum and CSF of NOMID patients. This led to the use of the humanized anti-IL6 receptor antibody, tocilizumab, to treat an infant with severe NOMID and interstitial lung disease who had a partial response to TNF inhibition and IL-1b inhibition with anakinra [38] . Although the acute-phase response markers improved, skin, eye and joint disease persisted on IL-6 inhibition and the child died from cardiac failure after 2 months of therapy. This patient had an earlier partial response to a maximal dose of 1.6 mg/kg day of anakinra, but higher doses of anakinra are often necessary to control disease and can be administered safely [34 ,39] .
The characteristic bony overgrowth seen in NOMID is the result of deranged endochondral bone formation, as evidenced by lack of palisading cartilaginous columns in the bone biopsy of the growth plate in one patient [40] .
Once established, this feature may not be controlled with anakinra therapy. An erosive arthritis affecting both small and large joints [41] was described in four generations of a French family with mutation-positive CAPS (T348M). Although the affected family members were HLA DR4 positive, they were anti-CCP and rheumatoid factor negative. A further feature in this family was the presence of demyelination on imaging; however, neurophysiologic testing and CSF analyses were normal.
Hyperimmunoglobulinemia-D with periodic fever syndrome: clinical aspects HIDS has traditionally been considered a benign disease, and typically symptoms resolve or greatly improve by the third decade. This has been challenged, not only by reports of AA amyloidosis in these patients, but also the description [42] of a 7-year-old female who developed macrophage activation syndrome (MAS) following a flare of HIDS. Differentiating MAS, a potentially deadly condition, from acute HIDS may be difficult; however, a drop in sedimentation rate despite ongoing clinical evidence of inflammation should trigger the consideration of MAS. One patient with a novel mutation in MVK resulting in severe mevalonate kinase deficiency developed glomerulonephritis that was unresponsive to steroid therapy whereas anakinra therapy resulted in resolution of proteinuria and fewer febrile episodes [43] .
Pediatric granulomatous arthritis: clinical aspects
An international registry [44 ] has provided further insights into Blau syndrome and early-onset sarcoidosis. Their data suggest that these conditions are equivalent clinically and the authors propose the use of the single term 'pediatric granulomatous arthritis' (PGA) to include both conditions. Patients with 'classic' features, namely arthritis, dermatitis and uveitis, bore specific mutations in NOD2/CARD15 whereas genetic testing in patients with atypical clinical features alone demonstrated no mutations. The authors suggest that genotyping in patients with 'classic' features may reduce the need for invasive procedures to confirm the diagnosis. In contrast to adult-onset sarcoidosis, lung disease is not a classical feature of PGA. In a patient diagnosed with Blau syndrome as an infant, however, lymphadenopathy with interstitial pneumonitis developed during his teenage years [45] . It is notable that there is no increase in NOD2/CARD15 mutations in patients with adult-onset sarcoidosis compared with controls [46] . TNF inhibition using infliximab but not etanercept was described as beneficial in a recent report of twins with PGA [47] .
Synovial biopsies from patients with Blau syndrome characteristically contain noncaseating granulomata [44 ] ; this is in contrast to the nonspecific inflammatory changes described in other autoinflammatory conditions. A lymphocyte-predominant chronic inflammatory infiltrate has been described in NOMID [48] , and sterile granulocytic infiltrate in FMF [49] .
Autoinflammatory diseases become more complex: new features and new members
Reports of the occurrence of autoinflammatory syndromes with common autoimmune diseases have emerged. One series found a 4 times increased prevalence of multiple sclerosis among FMF patients compared with expected rates in the Turkish population [50] . One patient with CAPS had concomitant biopsy-proven celiac disease [51] , which was also seen in two of the 12 patients in an Italian series of NOMID [11 ] . Determining whether a proinflammatory milieu due to excessive inflammasome activity contributes to the development of autoreactive T-cells and autoimmunity, will require further investigation.
The spectrum of autoinflammatory diseases continues to expand, with the recent inclusion of Schnitzler syndrome, the syndrome of urticaria-like skin rash and monoclonal gammopathy. Although CIAS1 mutations have not been detected in Schnitzler syndrome, anakinra therapy has been associated with a dramatic clinical response [52] . The disease spectrum of systemic onset juvenile inflammatory arthritis (SOJIA) and adult onset Still's disease (AOSD) has been suspected to belong to the group of autoinflammatory diseases, with response to anakinra notable in a subset of these patients [53] . Marked elevations of the proinflammatory cytokine IL-18 in patients with SOJIA, AOSD and, in particular, in MAS may provide early clues to their pathogenesis [53] [54] [55] . Behçet's disease has been considered an autoinflammatory disease [56] , but with no confirmed causative non-HLA genes identified. One study examined the frequency of mutations in genes associated with FMF, CAPS or PAPA (MEFV, CIAS1 and PSTPIP1), and found no increase in these mutations in Behçets patients compared with controls [57] . False hopes were raised when murine models of chronic recurrent multifocal osteomyelitis (CRMO), another suspected autoinflammatory disease, were found to have mutations in PSTPIP2 [58] . A closely related gene, PSTPIP1, was previously found to result in PAPA [59] . Disappointingly, to date, no mutations in PSTPIP1 or PSTPIP2 have been found in humans with CRMO [60] .
The role of 'danger recognition gone awry' in autoinflammatory diseases and beyond
While toll-like receptors (TLRs) have been recognized as innate immune sensors of extracellular 'danger' for some time [61, 62 ] , the recent discovery of new families of intracellular 'danger' sensors was pioneered by the discovery of pyrin. This protein, mutated in FMF, belongs to a larger family of TRIM proteins of which some members have been shown to sense intracellular 'danger' [63, 64 ] . The discovery that cryopyrin, the protein mutated in CAPS, carried a motif predicted to sense microbial 'danger' signals, added this protein to yet another family of intracellular 'danger' sensors, the NOD-like receptors, and spurred attempts to find their triggers [65] . The exciting data suggesting that cryopyrin is required for the detection of numerous 'danger' signals including bacteria, toxins, monosodium urate crystals that are released by necrotic cells, and calcium pyrophosphate dehydrate crystals [66 ,67 ,68 ,69 ] confirmed initial suspicions that cryopyrin played a crucial role in innate immunity. These findings have revolutionized not only our understanding of the physiology of danger recognition but also provided us with a model to test how flares in rheumatic conditions may be triggered. The discovery of the pathogenesis of both gout and pseudogout is an example of this revolution, as evidenced by the discovery that monosodium urate crystals activate the cryopyrin inflammasome to release IL-1b [70 ] . Although the inflammatory response in gout may be amplified via MyD88-mediated cytokine production [71 ,72] , the clinical response of nine of 10 gout patients to IL-1 blockade in an open-label proof of concept study clinically confirms the role of IL-1b oversecretion in gout [73] .
Initial observations regarding the role of the innate immune system in other common rheumatic diseases including rheumatoid arthritis, dermatomyositis and systemic lupus erythematosus (SLE) [74,75,76 ,77] will require further investigation. Interestingly, in SLE, abnormal TLR signaling is, in part, responsible for the interferon signature seen in this disease, which strongly suggests that a dysregulation in the innate immune system may contribute to the pathogenesis of SLE [78 ,79] . The clinical efficacy of hydroxychloroquine in SLE has been partially attributed to the inhibition of certain TLRs [80 ] . The finding that anti-Ro52/SSA, an antibody commonly found in SLE and Sjö gren's targets TRIM 21, a molecule similar to pyrin [81] , may provide further clues of the involvement of the innate immune system in SLE. Future studies need to explore the concept that in polygenic conditions such as SLE, minor alterations in both the innate and adaptive immune system may be required to result in clinical disease.
Conclusion
The discovery of genes underlying the monogenic autoinflammatory syndromes has not only led to a better understanding of the pathogenesis of these conditions but also provided rational targets for anticytokine therapy.
The evolving description of the molecular pathways that lead to danger recognition and signaling may provide new targets for drug development. While great strides have been made in our understanding of autoinflammation in monogenic diseases and, consequently, the innate immunity, much work remains to be done, especially regarding the involvement of the innate immune system in the more common rheumatic diseases.
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